[
    {
        "content": "* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN\u200d\u200b Source text (http://bit.ly/2zxBcXv) Further company coverage:",
        "date": "11102017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald "
    },
    {
        "content": "* Nektar Therapeutics reports financial results for the third quarter of 2017",
        "date": "11072017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39 "
    },
    {
        "content": "* Presents preclinical data on NKTR-358  a first-in-class regulatory T Cell stimulator  at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:",
        "date": "11072017",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358 "
    },
    {
        "content": "* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214  a CD122-biased agonist  with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:",
        "date": "09122017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics initiates propel clinical study "
    },
    {
        "content": "* Nektar Therapeutics - Co  Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:",
        "date": "08252017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement "
    },
    {
        "content": "* Nektar therapeutics reports financial results for the second quarter of 2017",
        "date": "08082017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics Q2 loss per share $0.39 "
    },
    {
        "content": "* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358  an autoimmune therapy",
        "date": "07242017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Eli Lilly and Nektar Therapeutics to develop  commercialize NKTR-358 "
    },
    {
        "content": "July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.",
        "date": "07212017",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "EMA panel recommends against Nektar  Daiichi Sankyo's breast cancer drug "
    },
    {
        "content": "* Presented new findings from two phase 1 clinical studies of NKTR-214  nektar's lead immuno-oncology candidate",
        "date": "06052017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214 "
    },
    {
        "content": "* Nektar Therapeutics reports financial results for the first quarter of 2017",
        "date": "05092017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics reports Q1 revenue $24.7 million "
    },
    {
        "content": "March 20 Nektar Therapeutics said its experimental opioid  designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids  succeeded in a key late-stage study.",
        "date": "03202017",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "Nektar's opioid painkiller succeeds in key late-stage study "
    },
    {
        "content": "* Co to discuss next steps with FDA  looks for strategic partner",
        "date": "03202017",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "UPDATE 2-Nektar's opioid painkiller succeeds in key late-stage study "
    },
    {
        "content": "* Nektar Therapeutics reports fourth quarter and year-end 2016 financial results",
        "date": "03012017",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics Q4 loss per share $0.28 "
    },
    {
        "content": "* Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214 at the society for immunotherapy of cancer (SITC) 2016 annual meeting",
        "date": "11092016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214 "
    },
    {
        "content": "* Nektar Therapeutics reports financial results for the third quarter of 2016",
        "date": "11032016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics reports financial results for Q3 "
    },
    {
        "content": "* Nektar therapeutics announces public offering of shares of common stock",
        "date": "10172016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics announces public offering of shares "
    },
    {
        "content": "Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.",
        "date": "09272016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "Bristol-Myers to test Opdivo with Nektar drug for several cancers "
    },
    {
        "content": "* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214",
        "date": "09272016",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration "
    },
    {
        "content": "* Nektar Therapeutics reports financial results for the second quarter of 2016",
        "date": "08032016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics reports Q2 loss per share $0.36 "
    },
    {
        "content": "* Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments",
        "date": "06012016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "CORRECTED-BRIEF-Nektar Therapeutics  Daiichi Sankyo Europe sign licensing deal for breast cancer drug "
    },
    {
        "content": "* In case of pre-conditional approval termination of deal  nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "06012016",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar says co may pay Daiichi $12.5 mln termination payment "
    },
    {
        "content": "* Nektar therapeutics reports financial results for the first quarter of 2016",
        "date": "05032016",
        "name": "Nektar Therapeutics",
        "news_type": "topStory",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics reports Q1 loss per share $0.14 "
    },
    {
        "content": "March 17 Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.",
        "date": "03172015",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "Nektar drug fails late-stage study in breast cancer patients "
    },
    {
        "content": "March 17 Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.",
        "date": "03172015",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "UPDATE 1-Nektar drug fails late-stage study in breast cancer patients "
    },
    {
        "content": "* Phase 3 study of NKTR-102 in patients with advanced breast cancer fails to show statistically significant improvement in overall survival",
        "date": "03172015",
        "name": "Nektar Therapeutics",
        "news_type": "normal",
        "symbol": "NKTR",
        "title": "BRIEF-Nektar Therapeutics' Phase 3 study of NKTR-102 fails to show significant improvement in overall survival "
    }
]